Pallas Capital Advisors’s Royalty Pharma RPRX Stock Holding History

Pallas Capital Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.09M	Buy	108,585 +5,616	+5%	+$292K	0.19%	95
2026 Q1	$4.94M	Sell	102,969 -8,157	-7%	-$357K	0.19%	106
2025 Q4	$4.29M	Buy	111,126 +6,544	+6%	+$250K	0.14%	120
2025 Q3	$3.69M	Buy	104,582 +1,341	+1%	+$48.5K	0.14%	124
2025 Q2	$3.72M	Buy	103,241 +2,794	+3%	+$92.6K	0.14%	120
2025 Q1	$3.13M	Buy	100,447 +8,113	+9%	+$257K	0.13%	137
2024 Q4	$2.36M	Buy	+92,334	New	+$2.45M	0.1%	147
2023 Q2	–	Sell	-20,982	Closed	-$752K	–	295
2023 Q1	$752K	Sell	20,982 -731	-3%	-$27.1K	0.07%	163
2022 Q4	$832K	Buy	+21,713	New	+$906K	0.08%	164

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pallas Capital Advisors's RPRX Position: Q2 2026 in Review

Pallas Capital Advisors increased its Royalty Pharma (RPRX) stake by 5.5% in Q2 2026, buying an estimated $292K and bringing the position to 108,585 shares worth $6.09M. The position accounts for 0.19% of the portfolio, ranked #95.

Pallas Capital Advisors first reported a position in RPRX in Q4 2022 and has held it in 9 quarters since. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Pallas Capital Advisors held 108,585 shares of Royalty Pharma worth $6.09M as of Q2 2026.
Pallas Capital Advisors bought 5,616 Royalty Pharma shares in Q2 2026, an estimated $292K.
Royalty Pharma made up 0.19% of Pallas Capital Advisors's portfolio in Q2 2026, its #95 holding.
Pallas Capital Advisors first reported a position in Royalty Pharma in Q4 2022 and has held it in 9 quarters since.
646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.